Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.
Type:
Grant
Filed:
July 21, 2008
Date of Patent:
December 25, 2012
Assignee:
Protaffin Biotechnologie AG
Inventors:
Andreas Kungl, Anna Maria Piccinini, Christian Weber
Abstract: The present invention relates to the use of a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated biological activity compared to the respective wild type IL-8 for preparing a medicament for the prevention and/or treatment of ischemia reperfusion injury and/or transplant rejection in patients.
Type:
Application
Filed:
August 28, 2007
Publication date:
September 22, 2011
Applicant:
Protaffin Biotechnologie AG
Inventors:
Andreas J. Kungl, Jens Bedke, Hermann-Josef Gröne
Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably ?1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.
Abstract: The present invention relates to a system for measuring the biological activity of chemoattractants comprising at least two units separated by a semipermeable carrier wherein biologically active carbohydrate structures, preferably glycosaminoglycan (GAG) structures, are immobilized on the surface of said carrier. According to the invention, this system can be used for fast and economic measurement of the degree of cell mobility and chemotactic activity.
Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably 1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.